nortriptyline 25mg tablets
alliance healthcare (distribution) ltd - nortriptyline hydrochloride - oral tablet - 25mg
nortriptyline 25mg tablets
alissa healthcare research ltd - nortriptyline hydrochloride - oral tablet - 25mg
nortriptyline 10mg tablets
alissa healthcare research ltd - nortriptyline hydrochloride - oral tablet - 10mg
patient positioning device, diagnostic imaging/radiotherapy, whole body
ge healthcare australia pty ltd - 40902 - patient positioning device, diagnostic imaging/radiotherapy, whole body - this device comprising of fixed or adjustable position elements is intended to ensure adequate positioning and/or immobilization of the patient's whole body during diagnostic imaging, image guided surgical or interventional procedures and/or radiation therapy procedures.
amitriptyline hydrochloride- amitriptyline hydrochloride tablet, film coated
cardinal health - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardi
amitriptyline hydrochloride- amitriptyline hydrochloride tablet, film coated
ncs healthcare of ky, inc dba vangard labs - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc
amitriptyline hydrochloride tablet, film coated
accord healthcare inc. - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc
patient positioning device, vacuum stabilized, whole body
jd healthcare group pty ltd - 35185 - patient positioning device, vacuum stabilized, whole body - olympic vac-pac? for patient positioning is a safe and supported method of quickly positioning patients for surgery. olympic vac-pac? conforms to the shape of the patient, holding them securely in place while providing medical care to selected areas of the body.
entrip amitriptyline hydrochloride 50 mg tablets blister pack
arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. entrip 50mg tablets are indicated only for the maintenance treatment of major depression (see precautions). nocturnal enuresis where organic pathology has been excluded.
entrip amitriptyline hydrochloride 25 mg tablets blister pack
arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 25 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. nocturnal enuresis where organic pathology has been excluded.